Alzheimers & Dementia
Scope & Guideline
Advancing the frontiers of dementia research.
Introduction
Aims and Scopes
- Neurobiology of Alzheimer's Disease:
Investigating the underlying biological mechanisms of Alzheimer's disease, including amyloid and tau pathology, neuroinflammation, and neurodegeneration. - Clinical and Diagnostic Biomarkers:
Development and validation of biomarkers for early detection, diagnosis, and monitoring of Alzheimer's disease progression, leveraging blood, CSF, and imaging techniques. - Treatment and Therapeutics:
Research on pharmacological and non-pharmacological interventions aimed at modifying disease progression and improving quality of life for patients. - Epidemiology and Risk Factors:
Exploring the epidemiology of Alzheimer's disease, including risk factors, prevalence, and the impact of comorbidities across diverse populations. - Socioeconomic and Behavioral Aspects:
Understanding the role of social determinants, caregiver experiences, and lifestyle factors in the context of Alzheimer's disease and dementia care. - Innovative Research Methodologies:
Utilizing cutting-edge technologies such as AI, machine learning, and multi-omics approaches to enhance research capabilities and data analysis.
Trending and Emerging
- Biomarker Development and Validation:
There is a growing emphasis on identifying and validating biomarkers for early diagnosis and progression tracking, particularly through blood-based assays and imaging techniques. - Digital Health and Technology Integration:
The integration of digital tools for cognitive assessment and monitoring, including AI and machine learning applications, is becoming increasingly significant in Alzheimer's research. - Neuroinflammation and Immune Response:
Research focusing on neuroinflammatory processes and the immune system's role in Alzheimer's disease is gaining traction, highlighting its potential for therapeutic targeting. - Lifestyle and Behavioral Interventions:
Emerging studies are exploring the impact of lifestyle modifications, such as diet and physical activity, on cognitive health and dementia risk reduction. - Longitudinal and Multi-Cohort Studies:
There is an increasing trend towards conducting long-term longitudinal studies that examine cognitive decline across diverse populations and various stages of Alzheimer's disease. - Health Disparities and Social Determinants:
Research addressing health disparities and the influence of social determinants on Alzheimer's disease prevalence and outcomes is becoming more prominent, reflecting a broader societal perspective.
Declining or Waning
- Traditional Neuropsychological Assessments:
There is a noticeable shift from reliance on traditional neuropsychological tests towards more innovative and objective measures, such as digital cognitive assessments and biomarkers. - Generalized Risk Factor Studies:
Research focusing broadly on risk factors without specific contextual application is declining in favor of studies that consider individual and population-specific variables. - Studies with Limited Diversity:
Research that does not address or include diverse populations is becoming less prevalent, as the field increasingly values inclusivity and representation in study designs. - Single-Domain Approaches:
There is a move away from single-domain studies towards integrated approaches that consider the multifactorial nature of Alzheimer's disease, including genetic, environmental, and lifestyle factors. - Basic Science without Translational Focus:
Basic science research that does not translate into clinical applications or implications is less favored, as the journal emphasizes studies that bridge the gap between laboratory findings and clinical practice.
Similar Journals
Current Alzheimer Research
Empowering the Fight Against Neurodegenerative DisordersCurrent Alzheimer Research is a pivotal journal dedicated to advancing knowledge in the field of neurology, with a particular focus on Alzheimer's disease and related neurodegenerative disorders. Published by BENTHAM SCIENCE PUBL LTD, this journal contributes to the growing body of literature aimed at bridging the gap between clinical research and practical application. Operating out of the United Arab Emirates, it has established itself as a reputable source for interdisciplinary research and clinical studies, reflecting its category quartiles ranking of Q3 in both Neurology and Clinical Neurology as of 2023. The journal, which spans from 2004 to 2024, provides scientists, clinicians, and students with up-to-date research findings while fostering an environment of knowledge exchange. Researchers are encouraged to submit their work, share insights, and engage with the latest discoveries that aim to enhance understanding and treatment strategies in Alzheimer’s disease, thereby addressing one of the most pressing challenges in neuroscience today.
Acta Facultatis Medicae Naissensis
Advancing Medical Knowledge Through Open AccessActa Facultatis Medicae Naissensis is an esteemed open-access journal published by the University of Niš, Faculty of Medicine, situated in Serbia. Since its inception in 2009, this journal has been a vital platform for the dissemination of innovative research findings in the field of Medicine, particularly focusing on miscellaneous areas within the discipline. With an ISSN of 0351-6083 and an E-ISSN of 2217-2521, it operates under a commitment to free accessibility, enhancing visibility for authors and readers alike since 2012. In the 2023 categorization, it holds a respectable Q4 ranking in Medicine (Miscellaneous) and positions itself at the 34th percentile among general medicine publications in Scopus, reflecting its growing academic impact. Researchers, professionals, and students seeking an interactive scholarly exchange in medicine will find Acta Facultatis Medicae Naissensis a rich resource, contributing significantly to the understanding of health sciences and clinical practice through its diverse range of articles.
JOURNAL OF ALZHEIMERS DISEASE
Connecting research and care for a brighter future.Journal of Alzheimer's Disease, published by IOS Press, stands as a pivotal resource in the fight against Alzheimer's and related neurodegenerative disorders. With an ISSN of 1387-2877 and an E-ISSN of 1875-8908, this esteemed journal has evolved since its inception in 1998, providing a vital platform for academic research and clinical practice in the realms of Clinical Psychology, Geriatrics and Gerontology, Neuroscience, and Psychiatry and Mental Health. Ranked in the Q1 category across several disciplines, including Clinical Psychology and Geriatrics, this journal not only highlights significant advancements in understanding Alzheimer's disease but also fosters interdisciplinary dialogue among researchers, healthcare professionals, and policymakers. Boasting robust Scopus rankings—such as 49th in Clinical Psychology and 29th in Geriatrics—this journal is committed to disseminating high-quality research that informs both therapeutic strategies and public health initiatives. The Journal of Alzheimer's Disease is an essential resource for anyone dedicated to exploring the complexities of cognitive decline and enhancing care for affected individuals.
NEUROBIOLOGY OF AGING
Fostering Insight into Aging's Impact on the Nervous SystemNEUROBIOLOGY OF AGING, published by Elsevier Science Inc, is a premier journal dedicated to advancing our understanding of the complex interactions between the aging process and neurobiological mechanisms. With an ISSN of 0197-4580 and E-ISSN 1558-1497, the journal has established itself as a critical resource in the fields of Aging, Developmental Biology, Geriatrics and Gerontology, Clinical Neurology, and Neuroscience. Boasting a Q1 ranking in multiple categories, the journal is positioned within the top echelons of scholarly publication, underscoring its significant impact with an impressive Scopus ranking in various subfields. Committed to disseminating high-quality, peer-reviewed research, NEUROBIOLOGY OF AGING welcomes original articles, reviews, and research notes aiming to uncover the underlying processes of aging on the nervous system, fostering collaboration among researchers, professionals, and students alike. Although primarily subscription-based, the journal continues to play a vital role in shaping the discourse on aging and neurobiology, making it an essential publication for those engaged in this dynamic field.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS
Unraveling the complexities of geriatric cognitive disorders.DEMENTIA AND GERIATRIC COGNITIVE DISORDERS is a distinguished peer-reviewed journal published by KARGER, based in Switzerland. With a focus on the critical fields of cognitive neuroscience, geriatrics, and psychiatry, this journal is integral to advancing our understanding of cognitive decline and geriatric health. Despite being established from 1990 through 1992 and relaunching its scope in 1994, it has consistently provided a platform for innovative research, as reflected in its strong impact factor and notable Scopus rankings, placing it in the Q2 quartile for disciplines including cognitive neuroscience and geriatric medicine. The journal aims to foster interdisciplinary dialogue and collaboration among researchers, healthcare professionals, and educators, contributing to the growing field of dementia research and elderly care. Open access options further ensure that this vital knowledge is widely accessible, making a significant impact in both academic and clinical settings. With a commitment to quality and relevance, DEMENTIA AND GERIATRIC COGNITIVE DISORDERS remains a key resource for those dedicated to understanding and addressing the challenges posed by cognitive disorders in aging populations.
Degenerative Neurological and Neuromuscular Disease
Exploring breakthroughs in neurological health.Degenerative Neurological and Neuromuscular Disease is a distinguished academic journal published by DOVE MEDICAL PRESS LTD, focusing on the latest advancements in the field of neurology and neuromuscular disorders. With a commitment to disseminating high-quality research, the journal aims to provide a critical platform for researchers, healthcare professionals, and students to share and engage with groundbreaking studies that advance our understanding of degenerative conditions affecting the nervous system. Although the journal's impact factor and h-index are currently not available, its open access model ensures that the valuable findings published within are accessible to a global audience, thereby fostering collaboration and innovation in neurological health. The journal's address is PO BOX 300-008, Albany, Auckland 0752, New Zealand, reflecting its international relevance and commitment to advancing the field of neurology. As the understanding of neurodegenerative diseases and neuromuscular challenges continues to evolve, Degenerative Neurological and Neuromuscular Disease serves as an essential resource for anyone dedicated to improving patient outcomes and advancing scientific knowledge.
NEUROPHARMACOLOGY
Transforming Research into Neuropharmacological BreakthroughsNEUROPHARMACOLOGY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a prestigious journal in the field of neuroscience and pharmacology, with a distinguished history dating back to 1962. With an ISSN of 0028-3908 and an E-ISSN of 1873-7064, the journal serves as a dynamic platform for the latest research that explores the intricate relationships between pharmacological agents and neural processes. Positioned in the Q1 quartile in both Cellular and Molecular Neuroscience and Pharmacology, it is recognized for its significant impact in the scientific community, boasting Scopus rankings of #36 in Pharmacology and #16 in Cellular and Molecular Neuroscience, underscoring its excellence and relevance. Although not an open access publication, its contributions are pivotal for researchers, professionals, and students sought to understand the complexities of neuropharmacological interactions. The journal aims to disseminate groundbreaking research findings, reviews, and perspectives that expand the frontiers of knowledge in the fields, making it an essential resource for anyone involved in neuroscience and pharmacology research.
NEUROLOGIST
Exploring the Frontiers of Neurological ScienceNEUROLOGIST, an esteemed journal published by Lippincott Williams & Wilkins, serves as a vital resource in the fields of Neurology and Medicine. With an ISSN of 1074-7931 and an E-ISSN of 2331-2637, this journal has been dedicated to advancing the understanding of neurological disorders since its inception in 1996, with continual contributions through 2024. Achieving a respectable Q3 rank in both Medicine (miscellaneous) and Neurology (clinical), it provides an essential platform for disseminating innovative research and clinical studies. Although it is not an open-access publication, NEUROLOGIST promotes a rich exchange of ideas and findings for researchers, healthcare professionals, and students alike, helping to bridge the gaps in neurological research and practice. The journal is recognized for its commitment to enhancing clinical practice and research methodology, making it a valuable asset for anyone engaged in the dynamic field of neurology.
CURRENT OPINION IN NEUROLOGY
Navigating the Evolving Landscape of Neurology.CURRENT OPINION IN NEUROLOGY is a premier academic journal dedicated to providing insightful overviews and critical analyses across all areas of neurology and clinical neurology. Published by Lippincott Williams & Wilkins, this esteemed journal boasts an impressive impact factor, highlighting its influence and relevance in the field—positioning it in the Q1 category for both neurology and clinical neurology as of 2023. With its comprehensive coverage, the journal serves as a vital resource for researchers, healthcare professionals, and students aiming to stay abreast of the latest developments, trends, and breakthroughs in neurological science and practice. Though not open access, articles are available via institutional subscriptions or individual purchase, ensuring that vital research remains accessible to a wide audience. Covering research from its inception in 1993 to ongoing studies in 2024, CURRENT OPINION IN NEUROLOGY stands out as an essential platform for disseminating knowledge and fostering dialogue within the dynamic and evolving landscape of neurology.
American Journal of Alzheimers Disease and Other Dementias
Pioneering research in dementia care and treatment.The American Journal of Alzheimer's Disease and Other Dementias, published by SAGE Publications Inc, is a pivotal resource for researchers, clinicians, and students engaged in the study of neurodegenerative diseases, particularly Alzheimer’s disease and various forms of dementia. With an impact factor reflecting its significance in the field, the journal boasts an open-access format since 2020, ensuring that groundbreaking research is accessible to a global audience. The journal holds prestigious Q2 rankings across several categories, including Clinical Psychology, Geriatrics and Gerontology, Neuroscience, and Psychiatry and Mental Health. Covering a wide spectrum from 1986 to 2024, it provides essential insights into innovative treatments, care strategies, and the latest findings in dementia research, solidifying its importance in fostering knowledge and advancing the field. With a commitment to high-quality scholarship, this journal is an indispensable tool for advancing understanding in the dynamic landscape of dementia studies.